Current reports
6-K
Procaps Announces Formation of Strategic Committee to Explore Value Creation Alternatives
4 Mar 24
6-K
Report of Foreign Private Issuer
24 Jan 24
6-K
Report of Foreign Private Issuer
16 Jan 24
6-K
Report of Foreign Private Issuer
5 Jan 24
6-K
Unaudited Condensed Consolidated Interim Financial Statements
26 Dec 23
6-K
Procaps Group Reports Third Quarter 2023 Results
26 Dec 23
6-K
Procaps Group Announces Appointment of Jose Antonio Vieira as Chief Executive Officer Starting 2024
22 Nov 23
6-K
Procaps Appoints Sandra Sánchez y Oldenhage to Board of Directors
23 Oct 23
6-K
Procaps Group Announces the Expansion of its Oncology Portfolio
7 Sep 23
6-K
Unaudited Condensed Consolidated Interim Financial Statements
5 Sep 23
Registration and prospectus
424B3
Prospectus supplement
1 Jun 23
POS AM
Prospectus update (post-effective amendment)
25 May 23
424B3
Prospectus supplement
14 Nov 22
424B3
Prospectus supplement
4 Nov 22
424B3
Prospectus supplement
2 Sep 22
424B3
Prospectus supplement
30 Aug 22
424B3
Prospectus supplement
15 Jun 22
424B3
Prospectus supplement
24 May 22
424B3
Prospectus supplement
6 May 22
POS AM
Prospectus update (post-effective amendment)
3 May 22
Proxies
No filings
Other
EFFECT
Notice of effectiveness
1 Jun 23
EFFECT
Notice of effectiveness
5 May 22
EFFECT
Notice of effectiveness
7 Dec 21
CORRESP
Correspondence with SEC
2 Dec 21
UPLOAD
Letter from SEC
1 Dec 21
CERT
Certification of approval for exchange listing
29 Sep 21
EFFECT
Notice of effectiveness
27 Aug 21
CORRESP
Correspondence with SEC
24 Aug 21
CORRESP
Correspondence with SEC
17 Aug 21
UPLOAD
Letter from SEC
13 Aug 21
Ownership
SC 13D/A
Hoche Partners Pharma Holding S.A.
20 Feb 24
SC 13D/A
Hoche Partners Pharma Holding S.A.
12 Jan 24
SC 13G
International Finance Corp
14 Feb 22
SC 13D
SOGNATORE TRUST
12 Oct 21
SC 13D
Hoche Partners Pharma Holding S.A.
12 Oct 21
3
Alexandre Weinstein Manieu
12 Oct 21
3
Ruben Minski
8 Oct 21
3
Jose Minski
8 Oct 21
3
Initial statement of insider ownership
8 Oct 21